# US 8,784,830 B2 · Antigen peptide and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,784,830 B2
- Document ID: US8784830B2
- Status: Granted
- Kind: B2
- Application number: 13/380,425
- Filed: 2011-05-23
- Published: 2012-11-29
- Granted: 2014-07-22
- Earliest claimed: 2010-05-27
- Applicants: Kenichiro Hasumi; Mikio Kuraya
- Inventors: Kenichiro Hasumi; Mikio Kuraya
- Web page: https://patentgrep.com/patent/US8784830B2

## CPC

- A61K 39/0208: {Specific bacteria not otherwise provided for}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 38/164: {from bacteria}
- A61K 39/05: {Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella}, Corynebacterium; Propionibacterium {(Mycobacterium A61K39/04)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/10: Anti-acne agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/195: from bacteria
- C07K 14/36: from Actinomyces; from Streptomyces (G)
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55588: {Adjuvants of undefined constitution}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/645: {Dendrimers; Multiple antigen peptides}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes.

## Claims

### Claim 1

A peptide consisting of the amino acid sequence of SEQ NO. 1.

### Claim 2 (depends on 1)

A fusion peptide, which is in a form of a multivalent antigen peptide comprising two or more of the peptide of claim 1 operably linked.

### Claim 3 (depends on 2)

A pharmaceutical composition for reducing inflammation caused by Propionibacterium acnes, comprising the fusion peptide as set forth in claim 2 and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, which is in the form of a solution, a suspension, a tablet, a pill, a capsule, a sustained release formulation or a powder.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, further comprising an adjuvant.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5, wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaoline, carbon, water-in-oil type emulsion, oil-in-water type emulsion, Muramyl dipeptide, bacterial endotoxin, fat X, Bordetella pertussis, Corynebacterium parvum, polyribonucleotide, sodium alginate, lanoline, lysolecithin, vitamin A, sponin, liposome, levamisole, DEAE-dextran, block copolymer, and combinations thereof.

### Claim 7 (depends on 2)

The fusion peptide of claim 2, wherein the two of more of the peptides are operably linked by a linker.

### Claim 8 (depends on 1)

A composition, comprising:
the peptide as set forth in claim 1, or a fusion peptide which is in a form of a multivalent antigen peptide comprising two or more of the peptide of claim 1 operably linked.

### Claim 9 (depends on 1)

A pharmaceutical composition for reducing inflammation caused by Propionibacterium acnes, comprising the peptide as set forth in claim 1 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, which is in the form of a solution, a suspension, a tablet, a pill, a capsule, a sustained release formulation or a powder.

### Claim 11 (depends on 9)

The pharmaceutical composition of claim 9, further comprising an adjuvant.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (alum), beryllium sulfate, silica, kaoline, carbon, water-in-oil type emulsion, oil-in-water type emulsion, Muramyl dipeptide, bacterial endotoxin, fat X, Bordetella pertussis, Corynebacterium parvum, polyribonucleotide, sodium alginate, lanoline, lysolecithin, vitamin A, sponin, liposome, levamisole, DEAE-dextran, block copolymer, and combinations thereof.